Abstract
We tested the effects of Oenanthe javanica (OJ) on hepatic fat accumulation and plasma biochemical profiles in a nonalcoholic fatty liver disease model (NAFLD). Rats were divided 5 groups and fed the following diets for 6 weeks: normal rat chow diet (CHOW), high-fat highcholesterol diet (HFCD), HFCD with the water extract of OJ (HFCD+W), HFCD with the nbutanol extract of OJ (HFCD+B), and HFCD with metadoxine (HFCD+M). Metadoxine (pyridoxine-pyrrolidone-carboxylate) is being used to treat alcoholic fatty liver and has been suggested that it can be effective for treating NAFLD. The HFCD gained significantly more body weight and visceral fat mass and had significantly higher levels of plasma glucose, triglyceride, cholesterol, and liver triglyceride content than the CHOW. The water- and n-butanol extracts of OJ improved the elevated plasma triglyceride and glucose levels induced by high-fat highcholesterol diet and lowered triglyceride content in the liver. Similarly, the treatment with metadoxine reversed the increased plasma glucose and triglyceride and showed a tendency to decrease hepatic fat accumulation. However, these supplements did not change body weight or visceral fat mass. These results indicate that OJ extracts improve changes in hepatic fat accumulation, plasma glucose, and lipid profiles induced by high-fat high-cholesterol diet but did not affect visceral obesity. In conclusion, the water- and n-butanol extracts of OJ and metadoxine improved hepatic fat accumulation, hyperglycemia, and dyslipidemia induced by high-fat highcholesterol diet although the effect of metadoxine on fatty liver was not significant, suggesting their potential use for the prevention and treatment of NAFLD.
Similar content being viewed by others
Abbreviations
- ALT:
-
alanine aminotransferase
- AST:
-
aspartate aminotransferase
- B:
-
n-butanol-extract
- FABP:
-
fatty-acid binding protein
- HFCD:
-
high-fat high-cholesterol diet group
- M:
-
metadoxine
- NAFLD:
-
nonalcoholic fatty liver disease model
- OJ:
-
Oenanthe javanica
- W:
-
water-extract
References
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346, 1221–1231.
Caballería J, Parés A, Brú C, Mercader J, García Plaza A, Caballería L, Clemente G, Rodrigo L, and Rodés J (1998) Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 28, 54–60.
Carmiel-Haggai M, Cederbaum AI, and Nieto N (2003) Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 125, 1818–1833.
Choudhury J and Sanyal AJ (2004) Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8, 575–594.
Fehér J and Lengyel G (2003) A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res 31, 537–551.
Fehér J, Váli L, Blázovics A, and Lengyel G (2009) The beneficial effect of metadoxine (pyridoxine-pyrrolidonecarboxylate) in the treatment of fatty liver diseases. Clin Exp Med J 3, 65–79.
Folch J, Sloane M, and Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226, 497–509.
Frayn KN and Maycock PF (1980) Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. J Lipid Res 21, 139–144.
Han YQ, Huang ZM, Yang XB, Liu HZ, and Wu GX (2008) In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica. J Ethnopharmacol 118, 148–153.
Kadayifci A, Merriman RB, and Bass NM (2007). Medical treatment of non-alcoholic steatohepatitis. Clin Liver Dis 11, 119–140.
Kim JY, Kim KH, Lee YJ, Lee SH, Park JC, and Nam DH (2009) Accelerative ethanol Metabolism by Oenanthe javanica Extract in ethanol-treated animals BMB Rep 42, 482–485.
Koruk M, Savaf MC, Yilmaz O, Tayfi S, Karakok M, Gündoðdu C, and Yilmaz A (2003) Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 37, 177–182.
Koteish A and Diehl AM (2001) Animal models of steatosis. Semin Liver Dis 21, 89–104.
Kral JG, Schaffner F, Pierson RN Jr, and Wang J (1993) Body fat topography as an independent predictor of fatty liver. Metabolism 42, 548–551.
Kwon DY, Jung YS, Kim SJ, Park HK, Park JH, and Kim YC (2009) Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 139, 63–68.
Lam BP and Younossi ZM (2009) Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 8, S51-S59.
Lazo M and Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28, 339–350.
Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, Sturek M, and Chalasani N (2009) Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 50, 56–67.
Li SZ (1978) Compendium of Materia Medica. People’s Medical Publishing House, Beijing, China, pp. 1632–1633.
Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, and Hotamisligil GS (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1, 107–119.
Maeda K, Uysal KT, Makowski L, Görgün CZ, Atsumi G, Parker RA, Brüning J, Hertzel AV, Bernlohr DA, and Hotamisligil GS (2003) Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 52, 300–307.
Malaguarnera M, Di Rosa M, Nicoletti F, and Malaguarnera L (2009) Molecular mechanisms involved in NAFLD progression. J Mol Med 87, 679–695.
Malhi H and Gores GJ (2008) Cellular and molecular mechanisms of liver injury. Gastroenterol 134, 1641–1654.
Marchi S, Polloni A, Costa F, Bellini M, Bonifazi V, Tumino E, Grassi B, Romano MR, De Bartolo G, Bertelli A, et al. (1990) Liver triglyceride accumulation after chronic ethanol administration: a possible protective role of metadoxina and ubiquinone. Int J Tissue React 12, 247–250.
McCullough AJ (2002) Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34, 255–262.
Nishina PM, Lowe S, Wang J, and Paigen B (1994) Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 43, 549–553.
Park JC, Kim JY, Lee YJ, Lee JS, Kim BG, Lee SH, and Nam DH (2008) Protective effect Oenanthe javanica extract on acetaminophen-induced hepatotoxicity in rats. Yakhak Hoeji 52, 316–321.
Park JC, Yu YB, Lee JH, Hattori M, Lee CK, and Choi JW (1996) Protective effect of Oenanthe javanica on the hepatic lipid peroxidation in bromobenzene-treated rats and its bioactive component. Planta Med 62, 488–490.
Polyzos SA, Kountouras J, and Zavos C. (2009) Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9, 299–314.
Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, and Ibdah JA (2008) Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 294, G619–626.
Shoelson SE, Herrero L, and Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterol 132, 2169–2180.
Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106, 171–176.
Torres DM and Harrison SA (2008) Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterol 134, 1682–1698.
Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, and Hotamisligil GS (2000) Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinol 141, 3388–3396.
Vuppalanchi R and Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49, 306–317.
Yang SQ, Lin HZ, Lane MD, Clemens M, and Diehl AM (1997) Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94, 2557–2562.
Yang XB, Huang ZM, Cao WB, Zheng M, Chen HY, and Zhang JZ (2000) Antidiabetic effect of Oenanthe javanica flavone. Acta Pharmacol Sin 21, 239–242.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jeong, YY., Lee, Y.J., Lee, KM. et al. The effects of Oenanthe javanica extracts on hepatic fat accumulation and plasma biochemical profiles in a nonalcoholic fatty liver disease model. J. Korean Soc. Appl. Biol. Chem. 52, 632–637 (2009). https://doi.org/10.3839/jksabc.2009.105
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.3839/jksabc.2009.105